Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Hieken TJ, et al. Among authors: markovic sn. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. Nat Commun. 2024. PMID: 38365756 Free PMC article. Clinical Trial.
Phase II trial of KW2189 in patients with advanced malignant melanoma.
Markovic SN, Suman VJ, Vukov AM, Fitch TR, Hillman DW, Adjei AA, Alberts SR, Kaur JS, Braich TA, Leitch JM, Creagan ET. Markovic SN, et al. Am J Clin Oncol. 2002 Jun;25(3):308-12. doi: 10.1097/00000421-200206000-00022. Am J Clin Oncol. 2002. PMID: 12040295 Clinical Trial.
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis.
Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET; Melanoma Study Group of the Mayo Clinic Cancer Center. Markovic SN, et al. Mayo Clin Proc. 2007 Mar;82(3):364-80. doi: 10.4065/82.3.364. Mayo Clin Proc. 2007. PMID: 17352373 Review.
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment.
Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET; Melanoma Study Group of Mayo Clinic Cancer Center. Markovic SN, et al. Mayo Clin Proc. 2007 Apr;82(4):490-513. doi: 10.4065/82.4.490. Mayo Clin Proc. 2007. PMID: 17418079 Review.
Malignant melanoma in the 21st century: the emerging molecular landscape.
Sekulic A, Haluska P Jr, Miller AJ, Genebriera De Lamo J, Ejadi S, Pulido JS, Salomao DR, Thorland EC, Vile RG, Swanson DL, Pockaj BA, Laman SD, Pittelkow MR, Markovic SN; Melanoma Study Group of Mayo Clinic Cancer Center. Sekulic A, et al. Among authors: markovic sn. Mayo Clin Proc. 2008 Jul;83(7):825-46. doi: 10.4065/83.7.825. Mayo Clin Proc. 2008. PMID: 18613999 Free PMC article. Review.
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Perez DG, Suman VJ, Fitch TR, Amatruda T 3rd, Morton RF, Jilani SZ, Constantinou CL, Egner JR, Kottschade LA, Markovic SN. Perez DG, et al. Among authors: markovic sn. Cancer. 2009 Jan 1;115(1):119-27. doi: 10.1002/cncr.23987. Cancer. 2009. PMID: 19090009 Free PMC article. Clinical Trial.
293 results